Jesse Cristiano R, Bortolatto Cristiani F, Savegnago Lucielli, Rocha João B T, Nogueira Cristina W
Laboratório de Síntese, Reatividade e Avaliação Farmacológica e Toxicológica de Organocalcogênios, Centro de Ciências Naturais e Exatas, Universidade Federal de Santa Maria (UFSM), Santa Maria, CEP 97105-900, RS, Brazil.
Prog Neuropsychopharmacol Biol Psychiatry. 2008 Dec 12;32(8):1838-43. doi: 10.1016/j.pnpbp.2008.08.010. Epub 2008 Aug 23.
Tramadol is a centrally acting analgesic which is used mainly for the treatment of moderate or severe pain. It is a synthetic opioid in the aminocyclohexanol group that binds weakly to micro-opioid receptors. Since it has been suggested that both opioid and monoaminergic systems play a role in depressive disorders, tramadol has been studied in the forced swimming test (FST). The present study was designed to explore the antidepressant activity of tramadol in rat FST and its possible mechanisms of action. The involvement of L-arginine-nitric oxide (NO)-cyclic guanosine monophosphate (cGMP) signaling pathway in the antidepressant action of tramadol was investigated. Treatment with tramadol, given (30 min earlier) by oral route (p.o.) at the doses of 10, 20 and 40 mg/kg, decreased immobility time in the FST. Pretreatment of rats with L-arginine (250 mg/kg, intraperitoneal, i.p., a nitric oxide precursor) or sildenafil (5 mg/kg, i.p., a phosphodiesterase 5 inhibitor, PDE5) significantly reversed the reduction in immobility time elicited by tramadol (20 mg/kg, p.o.) in the FST. Treatment of animals with a sub-effective dose of tramadol (5 mg/kg, p.o.) produced a synergistic antidepressant-like effect with N(G)-nitro-L-arginine (L-NNA, 3 mg/kg, i.p., an inhibitor of nitric oxide synthase) or with 7-nitroindazole (7-NI, 9 mg/kg i.p., a specific neuronal nitric oxide synthase inhibitor) in the FST. Pretreatment of animals with methylene blue (3.75 mg/kg i.p., an inhibitor of NO synthase and soluble guanylate cyclase - sGC) or (1H-[1,2,4] oxadiazolo[4,3-a]quinoxalin-1-one) (ODQ, 2 mg/kg, i.p., a specific inhibitor of sGC) significantly caused a synergistic effect with a sub-effective dose of tramadol (5 mg/kg, p.o.) in the FST. In the present study, different doses of tramadol and the combination with the L-arginine-NO-cGMP pathway modulators had no effect on the locomotor activity of rats in the open-field test. Thus, our findings suggest that the acute administration of tramadol produces antidepressant-like effect in the rat FST by a mechanism that involves the inhibition of L-arginine-NO-cGMP pathway.
曲马多是一种中枢性镇痛药,主要用于治疗中度或重度疼痛。它是氨基环己醇类的合成阿片类药物,与微阿片受体的结合较弱。由于有研究表明阿片类和单胺能系统在抑郁症中均起作用,因此在强迫游泳试验(FST)中对曲马多进行了研究。本研究旨在探讨曲马多在大鼠FST中的抗抑郁活性及其可能的作用机制。研究了L-精氨酸-一氧化氮(NO)-环磷酸鸟苷(cGMP)信号通路在曲马多抗抑郁作用中的参与情况。以10、20和40mg/kg的剂量经口(p.o.)给予曲马多(提前30分钟)进行治疗,可减少FST中的不动时间。用L-精氨酸(250mg/kg,腹腔注射,i.p.,一种一氧化氮前体)或西地那非(5mg/kg,i.p.,一种磷酸二酯酶5抑制剂,PDE5)对大鼠进行预处理,可显著逆转曲马多(20mg/kg,p.o.)在FST中引起的不动时间减少。用亚有效剂量的曲马多(5mg/kg,p.o.)对动物进行治疗,与N(G)-硝基-L-精氨酸(L-NNA,3mg/kg,i.p.,一种一氧化氮合酶抑制剂)或7-硝基吲唑(7-NI,9mg/kg,i.p.,一种特异性神经元一氧化氮合酶抑制剂)在FST中产生协同抗抑郁样效应。用亚甲蓝(3.75mg/kg,i.p.,一种一氧化氮合酶和可溶性鸟苷酸环化酶-sGC的抑制剂)或(1H-[1,2,4]恶二唑并[4,3-a]喹喔啉-1-酮)(ODQ,2mg/kg,i.p.,一种sGC的特异性抑制剂)对动物进行预处理,在FST中与亚有效剂量的曲马多(5mg/kg,p.o.)显著产生协同效应。在本研究中,不同剂量的曲马多以及与L-精氨酸-NO-cGMP途径调节剂的组合对旷场试验中大鼠的运动活性没有影响。因此,我们的研究结果表明,曲马多的急性给药通过一种涉及抑制L-精氨酸-NO-cGMP途径的机制在大鼠FST中产生抗抑郁样效应。